Screening for Small-Airway Dysfunction in Nonsmokers

Abstract

Small-airway dysfunction (SAD) is an underrecognized but clinically significant contributor to respiratory morbidity, even among nonsmokers. Early identification of SAD in this population is crucial, as it can precede overt airway disease and contribute to symptom burden and reduced quality of life. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic strategies, and management approaches for SAD in nonsmokers. Recent advances in noninvasive screening tools and emerging therapies are discussed, with an emphasis on guideline-based recommendations and practical considerations for clinicians.

Introduction

Small-airway dysfunction refers to impairment in the peripheral airways, typically those less than 2 mm in diameter. Historically associated with smoking-related obstructive lung disease, SAD is increasingly recognized in nonsmokers due to environmental exposures, genetic predisposition, and comorbid respiratory conditions. Understanding the mechanisms, clinical implications, and optimal strategies for screening and intervention has become a priority, as early SAD may represent a window of opportunity for intervention before irreversible airway remodeling occurs.

Epidemiology / Disease Burden

SAD is prevalent among individuals without a history of smoking, with population-based studies suggesting an overall prevalence ranging from 10% to 20% in nonsmoking adults. The burden is higher in certain at-risk groups, including those with occupational exposures, pre-existing allergic or atopic conditions, and individuals residing in areas with high ambient air pollution. SAD in nonsmokers contributes to respiratory symptoms, decreased exercise tolerance, and may accelerate the progression to chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) in susceptible individuals.

Pathophysiology

The small airways are vulnerable to injury due to their large cumulative surface area and limited structural support. In nonsmokers, pathophysiological mechanisms involve persistent or recurrent inflammation, immune dysregulation, and airway remodeling. Inhaled irritants, allergens, and viral infections can induce epithelial damage, goblet cell hyperplasia, peribronchiolar fibrosis, and smooth muscle hypertrophy. These changes lead to airflow limitation, air trapping, and ventilation heterogeneity, which may be subclinical initially but can progress over time if unrecognized.

Risk Factors

Key risk factors for SAD in nonsmokers include exposure to indoor and outdoor air pollutants (such as particulate matter, nitrogen dioxide, and ozone), occupational dusts and fumes, recurrent respiratory tract infections, underlying atopy or asthma, obesity, and genetic susceptibility. Socioeconomic factors, such as poor housing ventilation and urban residence, also contribute. It is important to recognize that SAD may develop in the absence of any single identifiable risk factor, highlighting the need for vigilant clinical assessment in symptomatic nonsmokers.

Clinical Features

Patients with SAD may present with nonspecific symptoms, including exertional dyspnea, cough, wheeze, and chest tightness. Symptoms are often intermittent or mild, and may be attributed to other causes such as deconditioning or upper airway disease. Physical examination findings are typically subtle or absent. In some cases, small-airway involvement may be identified incidentally during spirometric evaluation for unrelated indications. Clinicians should maintain a high index of suspicion in nonsmokers with unexplained respiratory symptoms, especially if risk factors are present.

Diagnosis

Diagnosing SAD in nonsmokers requires a combination of clinical assessment and objective pulmonary function testing. Conventional spirometry may be insensitive in early disease, as the small airways contribute minimally to total airway resistance. Sensitive measures include the forced expiratory flow between 25% and 75% of forced vital capacity (FEF25-75), impulse oscillometry (IOS), and nitrogen washout tests (e.g., single-breath or multiple-breath). Imaging modalities such as high-resolution computed tomography (HRCT) can reveal air trapping and mosaic attenuation, but are not routinely used for screening due to cost and radiation exposure. Emerging biomarkers and exhaled breath analysis are under investigation for their utility in early detection. Screening should be considered in at-risk nonsmokers with persistent respiratory symptoms, even when spirometry is normal.

Treatment & Management

Management of SAD in nonsmokers focuses on addressing underlying risk factors and alleviating symptoms. Environmental control and reduction of exposure to pollutants or occupational irritants are foundational. Pharmacologic therapy may include inhaled corticosteroids in patients with eosinophilic inflammation or concomitant asthma, and bronchodilators for symptomatic relief. Pulmonary rehabilitation and patient education are recommended for those with exercise limitation. Close monitoring for progression to overt airway disease is essential. Early intervention has the potential to modify disease trajectory and improve long-term outcomes.

Recent Advances / Emerging Therapies

Recent advances in the noninvasive assessment of small-airway function, such as IOS and advanced imaging techniques, have improved the detection of early SAD in nonsmokers. Novel inhaled therapies targeting distal airway inflammation are in development, including ultrafine particle inhalers and biologics for selected patients with underlying allergic or eosinophilic phenotypes. Digital health tools and remote monitoring platforms are being studied to facilitate early identification and longitudinal follow-up. Ongoing research aims to clarify the role of anti-fibrotic agents and targeted immunomodulators in preventing irreversible airway remodeling.

Guideline Recommendations

Current guidelines emphasize the importance of considering SAD in nonsmokers with unexplained respiratory symptoms, particularly when risk factors are present. The Global Initiative for Asthma (GINA) and American Thoracic Society (ATS) recommend the use of advanced pulmonary function tests when spirometry is inconclusive. Environmental and occupational history should be routinely elicited. There is consensus that early detection and intervention are likely to yield better outcomes, though large-scale studies are needed to define optimal screening intervals and therapeutic thresholds in this population.

Conclusion

Small-airway dysfunction in nonsmokers is a clinically important but frequently underdiagnosed condition with significant implications for respiratory health. Early identification through sensitive screening methods and a high index of clinical suspicion is crucial, particularly in individuals with risk factors or persistent symptoms. Advances in diagnostic technology and therapeutic strategies are expanding the armamentarium for clinicians, offering hope for improved detection, intervention, and long-term patient outcomes. Continued research and guideline development will be essential to optimize care and reduce the burden of SAD in nonsmoking populations.